Home / Mesothelioma / Prognosis
Mesothelioma Prognosis and Survival:
Statistics and Key Factors
A mesothelioma prognosis estimates how the disease may progress and how a patient may respond to treatment. It depends on factors such as tumor location, disease extent, histological subtype, overall health, treatment eligibility and response to therapy. Published survival statistics describe groups of patients and cannot predict an individual outcome.
At A Glance — Pleural Mesothelioma Survival
Population statistics cannot predict an individual outcome.
Source: American Cancer Society, Survival Rates for Pleural Mesothelioma, SEER data for people diagnosed 2015–2021.1
Survival statistics describe outcomes observed in groups of patients and cannot predict an individual outcome.
Mesothelioma is considered an aggressive cancer. Published survival statistics describe outcomes observed in groups of patients and should not be interpreted as predictions for individual cases. Disease progression and response to treatment may differ substantially from person to person.
Recent advances have expanded the range of treatment options available for mesothelioma. Immunotherapy, new drug regimens, specialized surgical techniques, and participation in clinical trials may provide additional possibilities for selected patients. Outcomes for patients diagnosed today may therefore differ from those reported in older survival statistics.
Only a physician who has carefully reviewed a patient’s medical history, pathology, imaging, overall health, and response to treatment can offer a meaningful discussion of individual prognosis.
Explore This Topic
Evidence Summary
The American Cancer Society reports an overall five-year relative survival rate of 15% for pleural mesothelioma diagnosed in the United States between 2015 and 2021, ranging from 23% for localized disease to 11% for distant disease. These are population statistics and cannot predict an individual outcome.1
Prognostic Factors
Physicians weigh several factors together when assessing prognosis, including disease stage, histological cell type, lymph-node involvement, resectability, performance status, and response to treatment. No single factor determines survival.
Treatment Context
Results from clinical trials represent average outcomes in selected patient groups and should not be used to predict the prognosis of an individual patient. Reported approaches include immunotherapy combinations, chemotherapy regimens, and surgery in carefully selected cases.
Key Facts
- Prognosis may vary considerably from one patient to another.
- Cancer location, stage, histological subtype, overall health, and eligibility for treatment are among the most important factors influencing prognosis.
- Epithelioid mesothelioma is usually associated with a more favorable prognosis than sarcomatoid or biphasic subtypes.4
- Earlier-stage and more localized disease may allow for a wider range of treatment options.
- Some patients with peritoneal mesothelioma may experience longer survival after cytoreductive surgery combined with hyperthermic intraperitoneal chemotherapy (CRS-HIPEC), appropriate only for carefully selected patients treated at experienced centers.2
What Does Mesothelioma Prognosis Mean?
A prognosis is a physician’s assessment of the likely course of a disease. It may include:
- how the cancer is expected to develop;
- whether it appears localized or has spread;
- which treatments may be possible;
- the likelihood that the tumor will respond to treatment;
- the possibility of recurrence or progression;
- expected symptom burden and quality of life;
- estimated survival based on comparable patient groups.
A prognosis is not a definitive prediction and may be revised as new diagnostic information emerges or as the medical team observes the disease’s response to treatment. For example, an initial prognosis may be revised after pathology establishes the cell subtype, after PET or CT imaging clarifies the extent of disease, or after treatment produces a significant response.
Prognosis, Life Expectancy, and Survival Rate
These terms are related but do not mean the same thing.
Median survival refers to the time point at which half of the patients in a study are still alive, and half have died. A reported median survival of 18 months indicates that half of the study participants survived longer than 18 months, while the other half survived for a shorter duration. Individual outcomes may vary considerably from the median.
| Term | What it means | How to interpret it |
|---|---|---|
| Prognosis | A physician’s overall assessment of the likely course of the disease | A working estimate, not a guarantee — it can change as more information becomes available |
| Life expectancy | An estimate of how long a person may live after diagnosis | Based on group medians; individual outcomes vary widely |
| Median survival | The point at which half of a study group has died and half is still alive | Describes a study population, not any one patient |
| Survival rate | The percentage of people alive after a set time period (e.g., 5 years) | A population-level statistic, useful for context only |
| Relative survival rate | Survival compared to people of the same age and sex without the cancer | Adjusts for other causes of death, but still cannot predict an individual case |
The American Cancer Society emphasizes that relative survival rates cannot account for every factor affecting an individual patient, including general health, resectability, tumor biology, and response to treatment.1
Current Pleural Mesothelioma Survival Rates
The American Cancer Society publishes pleural mesothelioma statistics using data from the National Cancer Institute’s Surveillance, Epidemiology, and End Results (SEER) program. These figures are based on people diagnosed with pleural mesothelioma from 2015 through 2021.1
| SEER disease extent | Five-year relative survival |
|---|---|
| Localized | 23% |
| Regional | 15% |
| Distant | 11% |
| All stages combined | 15% |
Five-year relative survival rates for pleural mesothelioma among people diagnosed in the United States from 2015 through 2021. SEER disease-extent categories are not equivalent to AJCC stages and cannot predict an individual outcome.
Source: American Cancer Society, Survival Rates for Pleural Mesothelioma.1
Five-Year Relative Survival by SEER Disease Extent
Text alternative: five-year relative survival by SEER disease extent for pleural mesothelioma, 2015 to 2021 — localized 23 percent, regional 15 percent, distant 11 percent. This chart visualizes the same data already presented in the table above, which remains the primary data source.
Source: American Cancer Society analysis of SEER data for people diagnosed with pleural mesothelioma from 2015 through 2021. SEER categories are not equivalent to AJCC stages and cannot predict an individual outcome.
Limitations: these figures apply to the extent of cancer at diagnosis, combine people with different ages, health conditions, cell types, and treatments, and reflect treatments received several years earlier. They cannot predict how an individual patient will respond, and patients diagnosed in the current era may have access to newer treatment options not available to those in earlier datasets.
Understanding the Numbers Can Be Difficult
A mesothelioma specialist can explain how stage, histology and treatment eligibility relate to an individual case.
Mesothelioma Prognosis by Location
Mesothelioma can develop in several different anatomical locations. Prognosis and treatment options may vary significantly depending on where the disease arises.
| Location | Where it develops | Main prognosis consideration |
|---|---|---|
| Pleural | Lining around the lungs | Disease extent, histology, lymph-node status and treatment eligibility |
| Peritoneal | Lining of the abdominal cavity | Selected patients may be eligible for CRS-HIPEC |
| Pericardial | Membrane surrounding the heart | Very limited evidence because it is extremely rare |
| Testicular | Tunica vaginalis (membrane surrounding the testicle) | Outcomes depend on tumor extent, histological subtype and recurrence risk |
Pleural mesothelioma
Develops in the lining surrounding the lungs
Pleural mesothelioma develops in the lining that surrounds the lungs, known as the pleura, and is the form for which the most survival information is available. Its prognosis is influenced by disease extent, lymph-node involvement, histological subtype, resectability, lung function, performance status, and treatment response. Patients with localized disease, epithelioid histology, good performance status, and no lymph-node involvement may be eligible for treatment approaches that are not appropriate for those with more advanced disease.
Peritoneal mesothelioma
Develops in the lining of the abdominal cavity
Peritoneal mesothelioma develops in the lining of the abdominal cavity, known as the peritoneum. Prognosis for this form should not be estimated using statistics from pleural mesothelioma, as the diseases differ in important ways.
For selected patients, cytoreductive surgery combined with hyperthermic intraperitoneal chemotherapy (CRS-HIPEC) may be considered at an experienced center. In a multi-institutional registry of 401 treated patients, median overall survival was 53 months, and the reported five-year survival rate was 47%.2 In the same registry, grade 3 or 4 complications occurred in 31% of patients, and 2% died during the perioperative period. These risks underscore the importance of careful patient selection, multidisciplinary evaluation, and treatment at a center experienced in peritoneal mesothelioma.
These outcomes represent results in carefully selected patients eligible for major treatment interventions and should not be considered representative survival expectations for all individuals with peritoneal mesothelioma.
Pericardial mesothelioma
Develops in the membrane surrounding the heart
Pericardial mesothelioma develops in the membrane that surrounds the heart, called the pericardium. It is extremely rare, and there are no large modern datasets that provide reliable stage-specific survival estimates. Published outcomes for pericardial mesothelioma are usually based on individual case reports or small retrospective series. For this reason, treatment and prognosis should be discussed individually with an experienced specialist team.
Testicular mesothelioma
Develops in the membrane surrounding the testicle
Mesothelioma of the tunica vaginalis, the membrane surrounding the testicle, is also extremely rare. Because so few cases have been reported, generalized survival percentages found online may not accurately reflect individual prognosis. For individual treatment planning, factors such as tumor extent, surgical findings, histological subtype, and risk of recurrence are often more informative than generalized survival statistics.
Factors That Influence Mesothelioma Prognosis
No single factor determines survival. Physicians consider multiple clinical findings together when assessing prognosis.
Factors Associated With Prognosis
- Stage and extent of disease
- Histological cell type
- Lymph-node involvement
- Resectability
- Performance status
- Age and general health
- Response to treatment
- Completeness of macroscopic tumor removal
- Access to experienced multidisciplinary care
Stage and extent of disease
Earlier-stage or localized disease is usually associated with a more favorable prognosis because the cancer has involved fewer structures and may allow for a wider range of treatment options. Advanced disease may involve extensive growth in the chest, lymph nodes, the opposite side of the chest, the abdomen, bones, or other distant areas. The National Cancer Institute notes that patients with stage I disease usually have a better prognosis than those with more advanced stages. However, precise stage-specific estimates are limited because mesothelioma is rare.3
Histological cell type
Pathologists usually classify malignant mesothelioma as epithelioid, sarcomatoid, or biphasic (containing both epithelioid and sarcomatoid components). Epithelioid mesothelioma is usually associated with more favorable outcomes than sarcomatoid or biphasic mesothelioma. Histological subtype may also influence treatment selection and expected response. The NCI identifies non-epithelioid histology as an adverse prognostic factor in established mesothelioma prognostic models.3
Lymph-node involvement
Cancer identified in regional lymph nodes may indicate a greater likelihood of disease spread. For patients undergoing aggressive surgical treatment, negative lymph nodes have been associated with improved long-term survival. Nodal status is therefore an important part of staging and treatment planning.
Resectability
Resectability refers to whether the medical team believes visible disease can be removed safely and effectively through surgery. It depends on more than stage alone — doctors may consider tumor distribution, invasion of nearby structures, lymph-node involvement, distant spread, lung and heart function, general fitness, and expected surgical risk. A determination that the disease is unresectable does not mean that all treatment options are excluded. Systemic therapy, radiation for selected indications, procedures to relieve symptoms, palliative care, and clinical trial participation may still be appropriate.
Performance status
Performance status describes how well a person can perform ordinary daily activities. A person who remains active and independent may tolerate combination therapy better than someone who is medically frail or significantly limited by illness. An impaired Eastern Cooperative Oncology Group (ECOG) performance status is one of the factors associated with poorer survival in the EORTC prognostic model.7
Age and general health
Age can influence treatment tolerance, but chronological age alone does not determine prognosis. Doctors also consider heart and lung function, kidney and liver function, nutrition and muscle mass, other medical conditions, medications, frailty, and ability to recover from treatment. In some cases, an older patient in good medical condition may tolerate treatment more effectively than a younger individual with significant comorbidities.
Response to treatment
Imaging, symptoms, physical function, and laboratory tests may be used to assess treatment response. A tumor that shrinks or remains stable during therapy may be associated with a different prognosis than disease that progresses rapidly. Prognosis may therefore change during the course of treatment.
Completeness of macroscopic tumor removal
In diffuse pleural mesothelioma, achieving a true R0 resection with microscopically negative margins is generally not considered feasible. The tumor grows along extensive pleural surfaces, and microscopic cancer cells may remain even after a major operation. When cytoreductive surgery is performed, the surgical goal has traditionally been macroscopic complete resection — meaning no visible or palpable tumor remains at the end of the procedure, although microscopic disease may still be present.
The ability to achieve macroscopic complete resection may be considered together with histological subtype, lymph-node involvement, tumor distribution, cardiopulmonary fitness, and the experience of the treatment center. However, macroscopic tumor removal should not be interpreted as proof that surgery will improve survival in an individual patient.
Access to experienced multidisciplinary care
Mesothelioma is rare. Evaluation by a multidisciplinary team experienced in the disease may provide access to specialized pathology review, thoracic or peritoneal surgery assessment, systemic therapies, symptom management, and clinical trials. While specialist evaluation does not guarantee a specific outcome, it may help ensure that all relevant treatment options are thoroughly considered. Readers can use our Find a Specialist directory to begin identifying experienced centers.
Earlier-stage disease, epithelioid histology, limited lymph-node involvement, and good performance status may be associated with a more favorable outlook. None of these factors can predict an individual result.
How Treatment May Affect Prognosis
Nivolumab plus ipilimumab
The CheckMate 743 phase III trial compared nivolumab plus ipilimumab with platinum-based chemotherapy in previously untreated, unresectable pleural mesothelioma. Median overall survival was 18.1 months with nivolumab plus ipilimumab compared with 14.1 months with chemotherapy.5 The combination improved overall survival in the study population, although it may cause serious immune-related adverse effects and is not appropriate for every patient. The FDA approved nivolumab in combination with ipilimumab in October 2020 for the first-line treatment of adults with unresectable malignant pleural mesothelioma.
Pembrolizumab plus chemotherapy
In September 2024, the FDA approved pembrolizumab combined with pemetrexed and platinum chemotherapy for the first-line treatment of unresectable advanced or metastatic malignant pleural mesothelioma. In the KEYNOTE-483 trial, median overall survival was 17.3 months with pembrolizumab and chemotherapy compared with 16.1 months with chemotherapy alone.6 The combination was also associated with a higher objective response rate: 52% compared to 29% for chemotherapy alone.
Pemetrexed plus platinum chemotherapy
Platinum chemotherapy combined with pemetrexed has been an important treatment option for many patients with unresectable disease. In the phase III trial that established this regimen, median survival was 12.1 months with pemetrexed plus cisplatin compared to 9.3 months with cisplatin alone.8 These results are from an earlier era and should be interpreted in the context of the treatments that were available at that time.
Bevacizumab with chemotherapy
For selected patients without contraindications, bevacizumab has been studied in combination with cisplatin and pemetrexed. In the MAPS trial, median overall survival was 18.8 months with the three-drug combination compared to 16.1 months with cisplatin and pemetrexed alone.9 The addition of bevacizumab was also associated with increased rates of severe hypertension and blood clots.
Surgery and multimodal treatment
The role of major cytoreductive surgery in pleural mesothelioma remains controversial. In the phase III MARS 2 trial, patients with resectable pleural mesothelioma who received extended pleurectomy decortication and chemotherapy had a median overall survival of 19.3 months, compared with 24.8 months among patients who received chemotherapy without surgery. Serious adverse events were also substantially more frequent in the surgery group.10
These results do not support the routine use of extended pleurectomy decortication as a method of improving survival in the population studied. However, they do not mean that every surgical procedure or every carefully selected clinical situation is identical. Any consideration of major surgery should take place at an experienced mesothelioma center, weighing histological subtype, lymph-node involvement, tumor distribution, cardiopulmonary fitness, treatment goals, expected risks, uncertainty regarding survival benefit, and the availability of clinical trials. Procedures intended to control pleural fluid, obtain tissue, or relieve symptoms should be distinguished from major cytoreductive operations intended to remove visible tumor.
| Study | Population | Comparison | Median overall survival |
|---|---|---|---|
| CheckMate 7435 | Previously untreated unresectable pleural mesothelioma | Nivolumab plus ipilimumab vs. chemotherapy | 18.1 vs. 14.1 months |
| KEYNOTE-4836 | Unresectable advanced or metastatic pleural mesothelioma | Pembrolizumab plus chemotherapy vs. chemotherapy | 17.3 vs. 16.1 months |
| Vogelzang phase III8 | Malignant pleural mesothelioma | Pemetrexed plus cisplatin vs. cisplatin | 12.1 vs. 9.3 months |
| MAPS9 | Unresectable pleural mesothelioma | Bevacizumab triplet vs. chemotherapy | 18.8 vs. 16.1 months |
| MARS 210 | Resectable pleural mesothelioma | Surgery plus chemotherapy vs. chemotherapy | 19.3 vs. 24.8 months |
Results from different clinical trials should not be compared directly. These studies enrolled different patient populations, used different eligibility criteria, and were conducted during different treatment eras.
Supportive and palliative care
Supportive or palliative care is not limited to the final stages of illness. It can be provided alongside cancer-directed therapies. It may help manage breathlessness, pleural or abdominal fluid, pain, fatigue, appetite and nutrition problems, sleep problems, anxiety and emotional distress, and treatment side effects. Effective symptom management may help maintain daily functioning, enhance treatment tolerance, and support quality of life, even if it does not directly impact the underlying malignancy. Our Patient Resources hub links to further supportive-care and financial-assistance information.
Explore Mesothelioma Treatment Options
Review chemotherapy, immunotherapy, surgery and supportive care options.
Can a Mesothelioma Prognosis Improve?
A prognosis may change when additional testing shows the cancer is less extensive than initially suspected, expert pathology review changes the histological classification, a patient responds well to therapy, treatment controls the disease for an extended period, surgery becomes appropriate after specialist evaluation, a relevant clinical trial becomes available, or symptoms and overall health improve with supportive care.
However, no food, supplement, alternative therapy, exercise regimen, or lifestyle intervention has demonstrated efficacy in curing mesothelioma. Nutrition, physical activity, rehabilitation, and emotional support may assist patients in maintaining strength and coping with treatment. These supportive measures should complement, not replace, evidence-based oncology care. Supplements should be discussed with the medical team because some can interact with cancer treatments or increase treatment-related risks.
Long-Term Mesothelioma Survivors
Long-term survival can occur in mesothelioma, but it remains uncommon and cannot be predicted or assured. Patients who live substantially longer than population averages may have one or more favorable characteristics, such as localized disease, epithelioid histology, good performance status, limited lymph-node involvement, complete or near-complete cytoreduction in peritoneal disease, a durable response to systemic therapy, or eligibility for multimodal treatment.
Accounts of individual long-term survivors may provide encouragement, but they do not constitute medical evidence that a specific treatment will yield similar outcomes for other patients.
Prepare for Your Appointment
Save the questions below to discuss with your medical team.
Questions to Ask the Medical Team
Consider bringing these questions to your next appointment.
- What type and histological subtype of mesothelioma has been diagnosed?
- What is the stage or extent of the disease?
- Has a specialist reviewed the pathology?
- Is the cancer considered resectable or unresectable?
- What factors have the greatest influence on my prognosis?
- Which treatment options are appropriate in my situation?
- What is the goal of each treatment?
- How will treatment response be measured?
- Would a second opinion at a mesothelioma center be helpful?
- Are there clinical trials for which I may be eligible?
- How can symptoms and treatment side effects be managed?
- When should supportive or palliative care become involved?
Frequently Asked Questions
What is the average prognosis for mesothelioma?
There is no single prognosis that applies to every form or stage of mesothelioma. For pleural mesothelioma, the American Cancer Society reports a five-year relative survival rate of 15% across all SEER stages combined. Individual outcomes may be substantially different.
What is the five-year survival rate for pleural mesothelioma?
For people diagnosed from 2015 through 2021, the five-year relative survival rates were 23% for localized disease, 15% for regional disease, and 11% for distant disease.
Can someone survive mesothelioma for five years?
Yes. Some patients survive five years or longer, particularly within selected groups with favorable disease characteristics or durable treatment responses. However, long-term survival cannot be predicted or guaranteed for an individual.
Does stage determine how long someone will live?
Stage is important, but it is not the only factor. Histology, tumor location, lymph-node involvement, overall health, resectability, treatment received, and response to treatment also influence prognosis.
Which mesothelioma cell type has the best prognosis?
Epithelioid mesothelioma is usually associated with a more favorable prognosis than sarcomatoid or biphasic mesothelioma. The proportion of each cell pattern within a biphasic tumor may also be clinically relevant.
Does peritoneal mesothelioma have the same prognosis as pleural mesothelioma?
No. These diseases develop in different anatomical locations and are treated differently. Selected patients with peritoneal mesothelioma who receive cytoreductive surgery and HIPEC may experience much longer survival than typical pleural mesothelioma population averages.
Is mesothelioma curable?
Mesothelioma is difficult to cure because it often grows across large tissue surfaces and may be advanced at the time of diagnosis. Long-term disease control is possible in some selected patients, but no treatment can guarantee a cure.
Can a doctor predict an exact survival time?
No. A doctor may provide an estimated range based on clinical evidence and experience, but an exact survival time cannot be predicted for any individual.
Trusted Mesothelioma Resources
Readers seeking additional evidence-based information may consult:
- National Cancer Institute — detailed information about mesothelioma classification, prognosis, treatment evidence, and clinical trials.
- American Cancer Society — patient-friendly explanations of survival statistics and how to interpret them.
- SEER Program — United States population-level cancer statistics maintained by the National Cancer Institute.
- U.S. Food and Drug Administration — official information about approved mesothelioma treatments and supporting clinical trials.
- ClinicalTrials.gov — searchable information about registered mesothelioma studies and recruiting clinical trials.
- Cancer Research UK — mesothelioma information, survival statistics, treatment explanations, and patient support guidance.
References
- American Cancer Society. Survival Rates for Pleural Mesothelioma. Based on SEER data, National Cancer Institute, for people diagnosed 2015–2021.
- Yan TD, Deraco M, Baratti D, et al. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for malignant peritoneal mesothelioma: multi-institutional experience. J Clin Oncol. 2009. DOI: 10.1200/JCO.2009.23.9640.
- National Cancer Institute. Malignant Mesothelioma — prognostic factors and staging information.
- National Cancer Institute. Histological subtype as a prognostic factor in malignant mesothelioma, as summarized in NCI’s mesothelioma treatment reference.3
- Baas P, Scherpereel A, Nowak AK, et al. First-line nivolumab plus ipilimumab in unresectable malignant pleural mesothelioma (CheckMate 743): a multicentre, randomised, open-label, phase 3 trial. Lancet. 2021;397(10272):375–386. DOI: 10.1016/S0140-6736(20)32714-8.
- U.S. Food and Drug Administration approval announcement, as reported by The ASCO Post, September 17, 2024 (KEYNOTE-483 / CCTG IND.227). A full peer-reviewed journal citation was not independently confirmed at the time of writing; this reference reflects the official approval announcement.
- European Organisation for Research and Treatment of Cancer (EORTC) prognostic model for malignant pleural mesothelioma, as summarized in NCI’s mesothelioma treatment reference.3
- Vogelzang NJ, Rusthoven JJ, Symanowski J, et al. Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. J Clin Oncol. 2003;21(14):2636–2644. DOI: 10.1200/JCO.2003.11.136. PMID: 12860938.
- Zalcman G, Mazières J, Margery J, et al. Bevacizumab for newly diagnosed pleural mesothelioma in the Mesothelioma Avastin Cisplatin Pemetrexed Study (MAPS): a randomised, controlled, open-label, phase 3 trial. Lancet. 2016;387(10026):1405–1414. DOI: 10.1016/S0140-6736(15)01238-6. PMID: 26719230.
- Lim E, Waller D, Lau K, et al. Extended pleurectomy decortication and chemotherapy versus chemotherapy alone for pleural mesothelioma (MARS 2): a phase 3 randomised controlled trial. Lancet Respir Med. 2024. DOI: 10.1016/S2213-2600(24)00119-X.
Editorial and Medical Disclaimer
This article is intended for educational purposes and does not provide individual medical advice, diagnosis, treatment recommendations, or survival predictions. Mesothelioma treatment decisions require evaluation by qualified physicians who have reviewed the patient’s pathology, imaging, medical history, health status, preferences, and treatment goals.
Editorial status: Evidence-based editorial content, prepared by the MesotheliomaFeed Editorial Team.